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Azithromycin for child survival: digging without getting too 
dirty into the differential effect on cause-specific mortality
A decade ago, the astonishing and unexpected 
results of a trachoma trial in Ethiopia1 hinted at the 
exciting potential of mass azithromycin distribution 
to significantly reduce all-cause mortality in children 
by approximately 50%. In 2018, the Macrolides Oraux 
pour Réduire les Décès avec un Oeil sur la Résistance 
(MORDOR) multi-country study,2,3 designed to 
investigate the effect of mass biannual azithromycin 
distribution on all-cause mortality in children aged 
1–59 months in sub-Saharan African communities, 
corroborated these results—although with more modest 
and credible findings than the trachoma trial.1 The 
greatest reduction in all-cause mortality was observed in 
Niger, the site with the highest baseline mortality, where 
biannual mass distribution of azithromycin to children 
aged 1–59 months decreased all-cause mortality by 18% 
compared with placebo.2 The results of the MORDOR 
trial,2 however, raised many questions about the 
mechanisms by which azithromycin could have such an 
effect on child mortality. The direct and indirect (ie, herd 
protection) therapeutic and chemoprophylactic effects 
of macrolides against a series of pathogens (either 
carried asymptomatically or overtly causing disease), 
their immunomodulatory benefits, or their effect on 
the human microbiome by promoting a so-called 
protective composition (ie, against superinfections), 
are all plausible explanations; the contributions of 
which remain a matter of scientific speculation. There 
were high expectations of the MORDOR trial2 to clearly 
establish the necessary mechanisms underlying the 
effects of mass azithromycin distribution in reducing all-
cause mortality in children.
In this issue of The Lancet Global Health, 
Jeremy D Keenan and colleagues3 report verbal 
autopsy results for childhood deaths that occurred in 
communities located at the Niger site of the MORDOR 
trial and analyse the distribution of deaths among 
the two study groups in an effort to understand 
the mechanisms underlying the effects of mass 
azithromycin distribution. In total, the cause of 
death for 1566 children in the azithromycin group 
and 1735 children in the placebo group (91·3% of 
all child deaths reported by population censuses) 
were ascertained by verbal autopsy interviews. The 
results indicated that mass azithromycin distribution 
protected against deaths due to infectious diseases, 
with a third fewer deaths due to meningitis and 
dysentery in the azithromycin group versus the placebo 
group, and a fifth fewer deaths due to pneumonia 
and malaria. Notably, azithromycin did not appear 
to alter the overall distribution of causes of death 
when compared with placebo. Keenan and colleagues3 
concluded that, in a setting where the epidemiological 
transition (ie, the dominant burden of disease 
transitioning from infectious to non-communicable 
causes) had not yet occurred and where infections 
remain the major determinants of child survival, the 
broad antimicrobial activity of azithromycin would 
suffice to cause a general reduction in the number 
of child deaths due to infectious diseases, and 
consequently overall mortality.
One of the fundamental caveats of the study3 is the 
method used to ascertain cause of death—the verbal 
autopsy, which is a notably unreliable method.4 In the 
verbal autopsy, the probable cause of death of a child 
is ascertained by interviewing the child’s caregiver 
by use of a standardised questionnaire, the results of 
which are analysed by clinicians or inputted into an 
automated software programme. The 2007 version 
of the WHO verbal autopsy questionnaire was used at 
the Niger site of the MORDOR study.2,3 Verbal autopsies 
can reasonably depict trends in the distribution of 
causes of death at a community level, but cause of 
death can be misclassified at the individual level, 
especially for children with unspecific and overlapping 
symptomatologies. In addition, verbal autopsies 
generally include only a few syndromic diagnoses 
(17 diagnoses were included in the version used in the 
MORDOR study2,3), and they fail to request information 
about coexisting morbidities or about the series 
of events that led to the death. The advent of the 
minimally invasive autopsy,5 which is a robust method 
for ascertaining cause of death post mortem that was 
introduced within the past 5 years, has surpassed the 
verbal autopsy interview as a reference for ascertaining 
cause of death of individuals from any age group in 
See Articles page e288
Comment
e170 www.thelancet.com/lancetgh   Vol 8   February 2020
low-income and middle-income settings. Although 
the minimally invasive autopsy is not a feasible option 
beyond 24–48 h post mortem, which is a severe 
limitation, this method has already been implemented 
for mortality surveillance as part of the ambitious 
Child Health and Mortality Prevention Surveillance 
network programme, with high acceptability.6,7 Using 
the minimally invasive autopsy for at least a subset 
of child deaths in the MORDOR study2,3 could have 
provided more information and invaluable samples 
to identify the pathophysiological causes of death 
and investigate the potential reasons underlying the 
effects azithromycin on reducing overall mortality. 
Nevertheless, randomisation should have guaranteed 
that, irrespective of its weaknesses, the verbal autopsy 
method applied remained valid, at least for an initial 
depiction of the distribution of causes of death 
and for the differential effect of mass azithromycin 
distribution.
The subanalysis of the MORDOR study results by 
Keenan and colleagues3 raises further questions. 
The authors found no effect of mass azithromycin 
distribution on child deaths due to malnutrition, nor did 
they explore the neonatal period, in which nearly half 
of all deaths in children younger than 5 years currently 
occur.8 It is now imperative to study the potential effect 
of such a preventive intervention on these two high-
risk and susceptible groups. In addition, the long-term 
consequences of using a mass antibiotic administration 
approach on the emergence of antimicrobial resistance 
is an issue that remains unresolved. After trachoma 
control programmes, macrolide-resistant strains of 
Streptococcus pneumoniae and Escherichia coli were 
documented,9 and there is also evidence to suggest 
that the prevalence of macrolide resistance is increased 
with mass azithromycin distribution.10 Although 
Keenan and colleagues3 hypothesise that mass drug 
administration to children younger than 5 years 
might lead to less macrolide resistance than trachoma 
programmes in adults, it would be negligent to overlook 
the consequences of this life-saving intervention in 
potentially increasing the prevalence of life-threatening 
antimicrobial resistance in the aforementioned 
pathogens and other pathogens, which are the main 
causes of death among neonates and children in sub-
Saharan Africa.
In the current era of big data, in which the global 
health community is largely focused on attaining a 
better understanding of the causes of deaths in children, 
large randomised trials, such as the MORDOR study,2,3 
that aim to ascertain causes of child death in high 
mortality settings are welcomed and praised; however, 
we encourage the authors of the study3 to dig more 
profoundly into the precious opportunities that such 
trials provide.
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